Overview

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Status:
Terminated
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
Primary: • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: • To evaluate key clinical outcome assessments
Phase:
Phase 2
Details
Lead Sponsor:
Aclaris Therapeutics, Inc.
Treatments:
Pharmaceutical Solutions